First do no harm

Research and Practice in Thrombosis and Haemostasis, vol. 6, pp. e12694

Abstract

For prevention of thrombotic events in patients hospitalized because of COVID‐19, low molecular weight heparin (LMWH) and unfractionated heparin are the rational anticoagulants of choice, given that the overall majority of thromboses are of venous origin.1‐3 In view of the high incidence of venous thromboembolism in ward and in intensive care unit (ICU) patients, a plethora of 75 studies have been registered since the start of the COVID pandemic.4 The majority of these compared therapeutic doses, and to a lesser extent, intermediate doses, versus a standard prophylactic dosis of LMWH in two sets of hospitalized COVID‐19 patients (i.e., ward patients who were named moderately or not critically ill and ICU patients).

Authors 2

1. Menno Volkert Huisman corresponding Aachen Department of Medicine – Thrombosis and Hemostasis Leiden University Medical Center Leiden the Netherlands Dept of Medicine - Thrombosis and Hemostasis

   Leiden University Medical Center

   Affiliation as printed

   Department of Medicine - Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands

   Department of Medicine – Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands

2. Frederikus Albertus Klok Aachen Department of Medicine – Thrombosis and Hemostasis Leiden University Medical Center Leiden the Netherlands Dept of Medicine - Thrombosis and Hemostasis

   Leiden University Medical Center

   Affiliation as printed

   Department of Medicine - Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands

   Department of Medicine – Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands